Evidence map›Paper›PMID 33744875›Full record

ArticleMedical principles and practice : international journal of the Kuwait University, Health Science Centre2021

A Refinement of Clinical Tumor Marker Monitoring: Why Not Use an Inverse Value of Doubling Time?

Gintaras Zaleskis, Paulius Bosas, Albertas Ulys, Daiva Dabkevičiene, Neringa Dobrovolskiene, Bret Andrew Hudson, Vita Pašukoniene

Open access · diamondAbstract read
In one paragraph

Article in Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Gintaras ZaleskisNational Cancer Institute Lithuania, NVI, Vilnius, Lithuania.
Paulius BosasNational Cancer Institute Lithuania, NVI, Vilnius, Lithuania.
Albertas UlysNational Cancer Institute Lithuania, NVI, Vilnius, Lithuania.
Daiva DabkevičieneNational Cancer Institute Lithuania, NVI, Vilnius, Lithuania.
Neringa DobrovolskieneNational Cancer Institute Lithuania, NVI, Vilnius, Lithuania.
Bret Andrew HudsonInnovita Research, Ltd., Vilnius, Lithuania.
Vita PašukonieneNational Cancer Institute Lithuania, NVI, Vilnius, Lithuania.
National Cancer Institute · LTState Research Institute Centre for Innovative Medicine · LTVilnius Gediminas Technical University · LTVilnius University · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of this study was to compare prostate-specific antigen (PSA) kinetics - half-life time (HT), doubling time (DT), and elimination rate PSA (ePSA) in prostate cancer (PCa) monitoring. Implementation of ePSA in clinical practice could help simplify patient monitoring in the remission phase. MATERIALS AND

methodsA total of 49 PCa patients were examined by their PSA tests before prostatectomy and after 30 days, 91 days, and 24 months. Conventional PSA rate of change parameters (HT and DT) were compared to a new clinically understandable ePSA parameter.

resultsWe observed that implementation of inverse value (ePSA) rather than HT or DT has distinct advantages: (1) values are valid when PSA is unchanged (ePSA equals zero), (2) the concept of ePSA can be easily understood, as it is a growth fraction, (3) ePSA fluctuates within a narrow range and is thus easy to interpret, and (4) there are no mathematical flaws (no positive skewing).

conclusionExploring ePSA norm as ≤0% could help spot biochemical recurrence in a timely manner. Primary health care providers tend to use an irrelevant PSA threshold, that is, 4.0 ng/mL, in postoperative follow-up. The delayed referrals of patients in remission might be reduced if ePSA testing is adopted.

Indexed as

AgedAged, 80 and overBiomarkers, TumorHumansMaleMiddle AgedNeoplasm Recurrence, LocalPostnatal CarePredictive Value of TestsProstatectomyProstate-Specific AntigenProstatic NeoplasmsTime FactorsBiomarkers, TumorProstate-Specific AntigenCancer relapseProstate cancerProstate-specific antigenTumor markers

Identifiers

PMID33744875
PMCPMC8280408
OpenAlexW3138085824

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.